BRPI0915887B8 - derivados de indol macrocíclicos úteis como inibidores do vírus da hepatite c - Google Patents
derivados de indol macrocíclicos úteis como inibidores do vírus da hepatite cInfo
- Publication number
- BRPI0915887B8 BRPI0915887B8 BRPI0915887A BRPI0915887A BRPI0915887B8 BR PI0915887 B8 BRPI0915887 B8 BR PI0915887B8 BR PI0915887 A BRPI0915887 A BR PI0915887A BR PI0915887 A BRPI0915887 A BR PI0915887A BR PI0915887 B8 BRPI0915887 B8 BR PI0915887B8
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitors
- hepatitis
- virus
- indole derivatives
- derivatives useful
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 241000711549 Hepacivirus C Species 0.000 title abstract 2
- 229940054051 antipsychotic indole derivative Drugs 0.000 title abstract 2
- 150000002475 indoles Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08159965.6 | 2008-07-08 | ||
| EP08159965 | 2008-07-08 | ||
| EP08160254 | 2008-07-11 | ||
| EP08160254.2 | 2008-07-11 | ||
| EP08161743.3 | 2008-08-04 | ||
| EP08161743 | 2008-08-04 | ||
| PCT/EP2009/004942 WO2010003658A1 (en) | 2008-07-08 | 2009-07-08 | Macrocyclic indole derivatives useful as hepatitis c virus inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0915887A2 BRPI0915887A2 (pt) | 2015-11-03 |
| BRPI0915887B1 BRPI0915887B1 (pt) | 2020-02-18 |
| BRPI0915887B8 true BRPI0915887B8 (pt) | 2021-05-25 |
Family
ID=40972916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0915887A BRPI0915887B8 (pt) | 2008-07-08 | 2009-07-08 | derivados de indol macrocíclicos úteis como inibidores do vírus da hepatite c |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8921355B2 (enExample) |
| EP (1) | EP2310396B1 (enExample) |
| JP (2) | JP5426671B2 (enExample) |
| KR (1) | KR101640374B1 (enExample) |
| CN (1) | CN102089314B (enExample) |
| AP (1) | AP2743A (enExample) |
| AR (1) | AR072726A1 (enExample) |
| AU (1) | AU2009267389B8 (enExample) |
| BR (1) | BRPI0915887B8 (enExample) |
| CA (1) | CA2729307C (enExample) |
| CL (1) | CL2011000032A1 (enExample) |
| CO (1) | CO6351793A2 (enExample) |
| CR (1) | CR20110076A (enExample) |
| DK (1) | DK2310396T3 (enExample) |
| EA (1) | EA019008B1 (enExample) |
| EC (1) | ECSP11010750A (enExample) |
| ES (1) | ES2651038T3 (enExample) |
| HN (1) | HN2011000072A (enExample) |
| HR (1) | HRP20171892T1 (enExample) |
| HU (1) | HUE035244T2 (enExample) |
| IL (1) | IL210086A (enExample) |
| LT (1) | LT2310396T (enExample) |
| MX (1) | MX2011000276A (enExample) |
| NI (1) | NI201100010A (enExample) |
| NO (1) | NO2310396T3 (enExample) |
| NZ (2) | NZ603343A (enExample) |
| SI (1) | SI2310396T1 (enExample) |
| SV (1) | SV2011003796A (enExample) |
| TW (1) | TWI454476B (enExample) |
| UY (1) | UY31973A (enExample) |
| WO (1) | WO2010003658A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2389994T3 (es) | 2007-12-24 | 2012-11-05 | Janssen R&D Ireland | Indoles macrocíclicos como inhibidores del virus de la hepatitis C |
| TWI454476B (zh) * | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物 |
| UA108211C2 (uk) * | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
| SG10201506652QA (en) * | 2010-04-13 | 2015-10-29 | Janssen Pharmaceuticals Inc | Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside |
| JP5870098B2 (ja) * | 2010-06-24 | 2016-02-24 | ヤンセン・サイエンシズ・アイルランド・ユーシー | １３−シクロヘキシル−３−メトキシ−６−［メチル−（２−｛２−［メチル−（スルファモイル）−アミノ］−エトキシ｝−エチル）−カルバモイル］−７Ｈ−インドロ−［２，１−ａ］−［２］−ベンズアゼピン−１０−カルボン酸の製造 |
| HUE035751T2 (hu) | 2011-09-02 | 2018-08-28 | Novartis Ag | Gyulladásgátló szubsztituált ciklobuténdion vegyület kolinsó |
| US8716275B2 (en) * | 2011-10-20 | 2014-05-06 | Bristol-Myers Squibb Company | Compound for the treatment of hepatitis C |
| CN104780921A (zh) | 2012-08-31 | 2015-07-15 | 杨森制药公司 | Hcv的大环蛋白酶抑制剂、非核苷hcv抑制剂和利托那韦的组合 |
| WO2014152275A1 (en) * | 2013-03-14 | 2014-09-25 | Concert Pharmaceuticals, Inc. | Deuterium modified derivatives of the ns5b polymerase inhibitor tmc647055 |
| US10450263B2 (en) | 2017-02-10 | 2019-10-22 | Southern Research Institute | Benzo annulenes as antiviral agents |
| KR101974388B1 (ko) | 2017-06-23 | 2019-05-02 | (주)에니켐텍 | 알킬 디에틸렌 트리아민 유도체 및 이의 제조방법 |
| WO2019133574A2 (en) * | 2017-12-26 | 2019-07-04 | Southern Research Institute | Benzoannulene derivatives as antiviral agents |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
| US12060148B2 (en) | 2022-08-16 | 2024-08-13 | Honeywell International Inc. | Ground resonance detection and warning system and method |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| US20050267836A1 (en) * | 1996-03-25 | 2005-12-01 | Cfph, Llc | Method and system for transacting with a trading application |
| HUP0004421A3 (en) | 1996-04-23 | 2002-10-28 | Vertex Pharmaceuticals Inc Cam | Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme |
| AU6701598A (en) | 1997-03-14 | 1998-09-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of impdh enzyme |
| EP1964561A1 (en) | 1999-03-19 | 2008-09-03 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| US6891331B2 (en) | 2000-08-30 | 2005-05-10 | Matsushita Electric Industrial Co., Ltd. | Plasma display unit and production method thereof |
| MY153011A (en) | 2004-01-30 | 2014-12-31 | Medivir Ab | Hcv ns-3 serine protease inhibitors |
| US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| BRPI0615922A2 (pt) | 2005-09-02 | 2011-05-31 | Tibotec Pharm Ltd | benzodiazepinas como inibidores de hcv |
| US7399758B2 (en) | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| GB0522881D0 (en) | 2005-11-10 | 2005-12-21 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| WO2007092000A1 (en) | 2006-02-06 | 2007-08-16 | Bristol-Myers Squibb Company | Inhibitors of hcv replication |
| US7521443B2 (en) * | 2006-05-17 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7456166B2 (en) * | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521441B2 (en) | 2006-05-22 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521442B2 (en) * | 2006-05-25 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| JP2010505902A (ja) | 2006-10-10 | 2010-02-25 | メディヴィル・アクチエボラーグ | Ｈｃｖヌクレオシド阻害剤 |
| CN103224506A (zh) | 2006-12-20 | 2013-07-31 | P.安杰莱蒂分子生物学研究所 | 抗病毒的吲哚 |
| EP2178885A1 (en) * | 2007-07-17 | 2010-04-28 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic indole derivatives for the treatment of hepatitis c infections |
| TWI454476B (zh) * | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物 |
| TW201023858A (en) | 2008-09-18 | 2010-07-01 | Ortho Mcneil Janssen Pharm | Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside |
| CN104478868A (zh) | 2009-02-27 | 2015-04-01 | 奥索-麦克尼尔-詹森药品公司 | Hcv大环抑制剂的无定形盐 |
| SG10201506652QA (en) | 2010-04-13 | 2015-10-29 | Janssen Pharmaceuticals Inc | Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside |
| JP5870098B2 (ja) | 2010-06-24 | 2016-02-24 | ヤンセン・サイエンシズ・アイルランド・ユーシー | １３−シクロヘキシル−３−メトキシ−６−［メチル−（２−｛２−［メチル−（スルファモイル）−アミノ］−エトキシ｝−エチル）−カルバモイル］−７Ｈ−インドロ−［２，１−ａ］−［２］−ベンズアゼピン−１０−カルボン酸の製造 |
| CN104780921A (zh) | 2012-08-31 | 2015-07-15 | 杨森制药公司 | Hcv的大环蛋白酶抑制剂、非核苷hcv抑制剂和利托那韦的组合 |
-
2009
- 2009-07-07 TW TW098122947A patent/TWI454476B/zh not_active IP Right Cessation
- 2009-07-08 HU HUE09793887A patent/HUE035244T2/hu unknown
- 2009-07-08 JP JP2011517026A patent/JP5426671B2/ja not_active Expired - Fee Related
- 2009-07-08 CA CA2729307A patent/CA2729307C/en active Active
- 2009-07-08 EA EA201170153A patent/EA019008B1/ru not_active IP Right Cessation
- 2009-07-08 SI SI200931765T patent/SI2310396T1/en unknown
- 2009-07-08 US US13/000,583 patent/US8921355B2/en active Active
- 2009-07-08 WO PCT/EP2009/004942 patent/WO2010003658A1/en not_active Ceased
- 2009-07-08 NZ NZ603343A patent/NZ603343A/xx not_active IP Right Cessation
- 2009-07-08 HR HRP20171892TT patent/HRP20171892T1/hr unknown
- 2009-07-08 BR BRPI0915887A patent/BRPI0915887B8/pt active IP Right Grant
- 2009-07-08 NO NO09793887A patent/NO2310396T3/no unknown
- 2009-07-08 KR KR1020117002865A patent/KR101640374B1/ko not_active Expired - Fee Related
- 2009-07-08 DK DK09793887.2T patent/DK2310396T3/en active
- 2009-07-08 MX MX2011000276A patent/MX2011000276A/es active IP Right Grant
- 2009-07-08 CN CN200980127068.3A patent/CN102089314B/zh active Active
- 2009-07-08 AU AU2009267389A patent/AU2009267389B8/en not_active Ceased
- 2009-07-08 LT LTEP09793887.2T patent/LT2310396T/lt unknown
- 2009-07-08 NZ NZ590073A patent/NZ590073A/xx not_active IP Right Cessation
- 2009-07-08 ES ES09793887.2T patent/ES2651038T3/es active Active
- 2009-07-08 UY UY0001031973A patent/UY31973A/es unknown
- 2009-07-08 AP AP2010005521A patent/AP2743A/xx active
- 2009-07-08 AR ARP090102596A patent/AR072726A1/es unknown
- 2009-07-08 EP EP09793887.2A patent/EP2310396B1/en active Active
-
2010
- 2010-12-19 IL IL210086A patent/IL210086A/en not_active IP Right Cessation
- 2010-12-21 CO CO10160463A patent/CO6351793A2/es active IP Right Grant
-
2011
- 2011-01-06 NI NI2011000101A patent/NI201100010A/es unknown
- 2011-01-07 EC EC2011010750A patent/ECSP11010750A/es unknown
- 2011-01-07 CL CL2011000032A patent/CL2011000032A1/es unknown
- 2011-01-07 HN HN2011000072A patent/HN2011000072A/es unknown
- 2011-01-07 SV SV2011003796A patent/SV2011003796A/es unknown
- 2011-02-08 CR CR20110076A patent/CR20110076A/es unknown
-
2013
- 2013-03-15 US US13/836,168 patent/US9427440B2/en active Active
- 2013-08-28 JP JP2013176771A patent/JP5808370B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0915887B8 (pt) | derivados de indol macrocíclicos úteis como inibidores do vírus da hepatite c | |
| UY32759A (es) | Inhibidores del virus de la hepatitis c | |
| CO6390076A2 (es) | Inhibidores de hcv ns5a | |
| CO6390077A2 (es) | Inhibidores de hacv ns5a | |
| NI201500030A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| JO3603B1 (ar) | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي | |
| CL2008002538A1 (es) | Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral | |
| BR112014033080A2 (pt) | inibidores do vírus da hepatite c | |
| GT201400009A (es) | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk | |
| CL2008002539A1 (es) | Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral | |
| BR112016006651A8 (pt) | derivados de quinolizina substituídos, composição farmacêutica que os compreede e uso dos mesmos. | |
| BR112017028504A2 (pt) | derivados de sulfamoilarilamida ciclizada e uso dos mesmos como medicamentos para o tratamento da hepatite b | |
| MX2015014033A (es) | Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| UY32351A (es) | Compuestos de pirimidinil indol para uso como inhibidores de atr | |
| CR20120302A (es) | Derivados bencimidazol-imidazol | |
| UY31183A1 (es) | Derivados de pirazinona y procesos para su preparación | |
| BR112014030639A2 (pt) | inibidores macrocíclicos de vírus flaviviridae | |
| BR112014030630A2 (pt) | inibidores macrocíclicos de vírus flaviviridae | |
| BR112013007696A2 (pt) | composto, composição farmacêutica, usos do referido composto e da referida composição | |
| BR112012017382A2 (pt) | compostos inibidores de viroses flaviviridae, uso dos mesmos e composição farmacêutica | |
| BR112015028538A2 (pt) | derivados de sulfamoiltiofenamida e o uso dos mesmos como medicamentos para o tratamento da hepatite b | |
| BR112015020242A2 (pt) | sulfamoil-arilamidas e seu uso como medicamentos para o tratamento da hepatite b | |
| UA115069C2 (uk) | Конденсовані біциклічні похідні сульфамоїлу та їх застосування як лікарських препаратів для лікування гепатиту b | |
| CO6761335A2 (es) | Inhibidores del virus de la hepatitis c | |
| BR112014016157A8 (pt) | derivados heterobicíclicos como inibidores de vhc |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: JANSSEN R AND D IRELAND (IE) |
|
| B25A | Requested transfer of rights approved |
Owner name: JANSSEN SCIENCES IRELAND UC (IE) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/02/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |